# PhII ICb With/Without Erbitux in MBC Pts

Source: https://onco.cc/trials/nct00248287/  
OnCo record `nct00248287` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Carboplatin and Cetuximab in advanced solid tumours, run by US Oncology Research, active and no longer recruiting.

## Summary

PhII ICb With/Without Erbitux in MBC Pts is a phase 2 interventional study registered as NCT00248287 by US Oncology Research, with 154 participants enrolled, started 2005-07-28 and due to reach its primary completion in 2025-12. Interventions recorded: Irinotecan + Carboplatin and irinotecan + Carboplatin + erbitux. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00248287
- Phase: 2
- Setting: Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
- Sponsor: US Oncology Research
- Enrolled: 154

## Sources

- ClinicalTrials.gov NCT00248287: https://clinicaltrials.gov/study/NCT00248287

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cetuximab](https://onco.cc/drugs/cetuximab/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/), [McKesson / The US Oncology Network](https://onco.cc/companies/mckesson-us-oncology/), [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/nct00248287.json